REVIEW ARTICLE

Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies

Fabien Chauveau1 · Guillaume Becker2,3 · Hervé Boutin4,5,6

Received: 25 February 2021 / Accepted: 19 May 2021 / Published online: 13 August 2021 © The Author(s) 2021

Abstract

Purpose The prototypical TSPO radiotracer (R)-[11C]PK11195 has been used in humans for more than thirty years to visualize neuroinflammation in several pathologies. Alternative radiotracers have been developed to improve signal-to-noise ratio and started to be tested clinically in 2008. Here we examined the scientific value of these “(R)-[11C]PK11195 challengers” in clinical research to determine if they could supersede (R)-[11C]PK11195.

Methods A systematic MEDLINE (PubMed) search was performed (up to end of year 2020) to extract publications reporting TSPO PET in patients with identified pathologies, excluding studies in healthy subjects and methodological studies.

Results Of the 288 publications selected, 152 used 13 challengers, and 142 used (R)-[11C]PK11195. Over the last 20 years, the number of (R)-[11C]PK11195 studies remained stable (6 ± 3 per year), but was surpassed by the total number of challenger studies for the last 6 years. In total, 3914 patients underwent a TSPO PET scan, and 47% (1851 patients) received (R)-[11C]PK11195. The 2 main challengers were [11C]PBR28 (24%—938 patients) and [18F]FEPPA (11%—429 patients). Only one-in-ten patients (11%—447) underwent 2 TSPO scans, among whom 40 (1%) were scanned with 2 different TSPO radiotracers.

Conclusions Generally, challengers confirmed disease-specific initial (R)-[11C]PK11195 findings. However, while their better signal-to-noise ratio seems particularly useful in diseases with moderate and widespread neuroinflammation, most challengers present an allelic-dependent (Ala147Thr polymorphism) TSPO binding and genetic stratification is hindering their clinical implementation. As new challengers, insensitive to TSPO human polymorphism, are about to enter clinical evaluation, we propose this systematic review to be regularly updated (living review).

Keywords Translocator protein 18 kDa (TSPO) · Clinical PET imaging · (R)-[11C]PK11195 · Radiotracer · Neuroinflammation

Abbreviations

NDD Neurodegenerative diseases
MCI mild cognitive impairment
AD Alzheimer’s disease
PD(D) Parkinson’s disease (with dementia)
DLB dementia with Lewy Bodies
IRBD idiopathic rapid-eye-movement sleep behaviour disorder
MSA multiple system atrophy
FTD frontotemporal dementia
CBD corticobasal degeneration
PSP progressive supranuclear palsy
ALS amyotrophic lateral sclerosis
PLS primary lateral sclerosis

This article is part of the Topical Collection on Neurology

* Fabien Chauveau chauveau@cermep.fr
* Hervé Boutin herve.boutin@manchester.ac.uk

1 University of Lyon, Lyon Neuroscience Research Center (CRNL), CNRS UMR5292, INSERM U1028, University Lyon 1, Lyon, France
2 GIGA – CRC In Vivo Imaging, University Liege, Liege, Belgium
3 University of Lyon, CarMeN Laboratory, INSERM U1060, University Lyon 1, Hospices Civils Lyon, Lyon, France
4 Faculty of Biology Medicine and Health, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
5 Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
6 Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance & University of Manchester, Manchester, UK
Introduction

About 40 years ago, PK11195 [1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide] was the first ligand chemically unrelated to benzodiazepines, to label what was called at this time the peripheral benzodiazepine receptor (or omega-3 binding site) [1]. These terminologies arose from its pharmacology (high affinity for some benzodiazepines) and its preferential expression in peripheral tissues (myocardium, kidney and adrenals) [1, 2]. Now known as the translocator protein 18 kDa (TSPO) [3], this receptor was rapidly identified as over-expressed in brain lesions and thought to be a good marker of neurodegeneration notably in models of brain ischaemia [4, 5]. Once radiolabelled [6], one of the first application of [11C]PK11195 for Positron Emission Tomography (PET) was to image brain tumours [7, 8]. However, it was only in the mid- to late 1990’s that increased level of radiolabelled PK11195 R-enantiomer binding to TSPO was proven to be associated with microglial activation in many diseases or animal models [9–12]. Though the wide potential of neuroinflammation imaging with (R)-[11C]PK11195 (correct nomenclature according to latest consensus guidelines [13] and IUPAC rules [14]) was recognized in the early 2000’s [15], intrinsic limitations of this radiotracer (limited brain entry, poor signal-to-noise ratio, plasma protein binding) soon led to the development of so-called “second-generation” TSPO radioligands [16].

In 2008, we published the first systematic review of these “(R)-[11C]PK11195 challengers”, and listed 45 radiolabelled candidates [17], a number that has now reached more than 60 radiotracers belonging to various chemical classes [18]. However, at that time, most of these radioligands underwent only preclinical evaluation, and clinical evaluation of [11C]PK11195 challengers was in its infancy: only 4 tracers had been engaged in a first-in-man study, and 2 reports involved patients ([11C]DAA1106 in Alzheimer’s disease [19]; [11C]vinpocetine in multiple sclerosis [20]). Since then, many PET studies with (R)-[11C]PK11195 challengers have been designed for various pathologies. Here we used a systematic approach to examine the outcome of over a decade of clinical evaluation. Studies performed on healthy subjects and comparison of analysis methods were recently reviewed in detail by Cumming et al. [21] and are therefore not covered in this review. In contrast, we here concentrate on clinical studies in patients with defined pathology, performed with (R)-[11C]PK11195 or challengers, with the aim to answer the following questions:

- Has (R)-[11C]PK11195 been superseded by challengers in clinical studies?
- What is the scientific added-value brought by these challengers?

As an introductory contribution to this TSPO review series, this scoping review covers the full “scope” of neuroinflammation imaging applications. A scoping review uses a systematic approach to “charting” or “mapping” a broad research field, hence it does not include meta-analysis or assess the strength of evidence across studies [22]. Selected fields and pathologies are discussed in detail in other contributions. Our goals are to i) provide a quantitative overview of all clinical TSPO PET studies available so far, ii) highlight research gaps and advisable future steps for neuroinflammation imaging to realize its full potential.
Material and methods

This study followed the PRISMA-S and PRISMA-ScR guidelines (PRISMA extensions for reporting literature Searches in systematic reviews [23] and for Scoping Reviews [24], respectively). Both checklists (available from: http://prisma-statement.org/Extensions/) were filled and are provided as supplemental files. The protocol was not registered. Publications were identified by searching MEDLINE (PubMed) electronic database. The following string search was performed:

“((TSPO OR PBR OR (peripheral benzodiazepine receptor[MeSH Terms])) OR (peripheral AND benzodiazepine) OR ("microglial activation") OR ("microphagia activation")) AND (positron emission tomography[MeSH Terms] OR PET OR positron) NOT review[pt]”

with i) selection of the “Species = Humans” PubMed limit filter, and ii) final date limit of 2020/12/31. The search was not restricted to interventional studies, and retrieved 433 items (last run on May 2021). In addition to these records, were added: i) 36 recent records without MeSH terms assignment (therefore escaping the Humans filter of Pubmed); ii) 25 records identified through manual full-text assessment which were eligible but escaped the Pubmed search (because of vague description like “macrophage imaging” or “activated glia” and lack of subsequent PBR/TSPO assignment in MeSH terms).

The following criteria were used for inclusion or exclusion:

- Inclusion of any TSPO PET study performed on patients with a defined pathology (CNS or other);
- Exclusion of TSPO PET reports performed only on healthy subjects (first-in-man, dosimetry, quantification methods) or including patients without pathology being studied;
- Exclusion of SPECT studies.

One author (FC) screened the titles and the abstracts for eligibility. The resulting bibliographic database is available as a public, closed membership, Zotero group library (anyone can view, only admins can edit):

https://www.zotero.org/groups/2578974/living_systematic_review_on_tspos_pet/library.

Two authors (FC and GB) assessed all publications of potential relevance for inclusion and extracted data in a calibrated form (discussed and defined prior to filling). The data extraction form is provided as supplemental material (xls file) and contains the following information for each item: PMID, pathology (coded as a Zotero tag), radiotracer, number of patients/controls, number of patients scanned more than once (if any), treatment (evaluated through TSPO imaging, if any). In case of a new analysis on previously published cohort, the new record was included but the number of patients was set to null so as not count them twice. In case of new patients added to an existing cohort, the record was included, and only new patients were counted. No quality assessment of studies was performed. To summarize data, pathologies were classified into 9 main groups: neurodegenerative diseases, demyelinating diseases, mental disorders, encephalopathies and viral infections, vascular diseases, traumatic brain injury, neuro- oncology, epilepsy and other systemic inflammatory diseases. This simplified classification was performed for statistical overview only. It does not follow a strict methodology but is based on varying criteria such as clinical spectrum, underlying (neuro) pathology or genetic changes. The authors recognize this classification may be questioned or changed according to recent and future knowledge on specific pathologies. All authors reviewed the selected publications and summarised the most relevant findings.

Results

Figure 1 shows the flow diagram of the study selection process. A total of 288 publications were included, which reported the use of 14 radiotracers ((R)-[11C]PK11195 and 13 challengers). Approximately half of the studies (142) were conducted with (R)-[11C]PK11195, and half (152) with the other radiotracers. Of note, only 12 publications (4%) reported the use of more than one radiotracer (identified with the Zotero tag “multiple tracer”). While 6 of them used separate groups of patients, only 40 patients (from 6 studies) received two different radiotracers: (R)-[11C]PK11195 vs [11C]vinpocetine [20, 25]; (R)-[11C]PK11195 vs [18F]GE-180 [26]; (R)-[11C]PK11195 vs [18F]DPA-714 and [11C]DPA-713 vs [18F]DPA-714 [27]; [11C]DPA-713 vs [11C]PBR28 [28]; [11C]PBR28 vs [18F]PBR06 [29].

The number of publications using (R)-[11C]PK11195 has been keeping a rather stable level from the last 20 years (mean ± SD = 6 ± 3 reports per year over the period 2000–2019). Of note, 2020 results may be biased because the Pubmed search with a date limit of 2020/12/31 includes “epub ahead of print” items which will receive a definite date of publication during 2021. As shown in Fig. 2, the annual number of publications with challengers reached the level of (R)-[11C]PK11195 in 2012 (≥ 5 studies each) and has now surpassed the number of (R)-[11C]PK11195 studies for the last 6 years (2015–2020).
An impressive variety of diseases have been explored: nearly 50 tags were used to classify all pathological conditions on Zotero (according to their description in included publications), which were gathered into 9 main groups (Fig. 3). The publications can be split into 3 thirds: one third for the neurodegenerative diseases, one third for mental disorders and demyelinating diseases, and one third for all the remaining diseases including encephalopathies and viral infections, vascular diseases, neuro-oncology, traumatic brain injury, epilepsy and other systemic inflammatory diseases. Imaging was not restricted to brain, as peripheral imaging was reported in 15 publications (vascular: 4; articular and spinal cord: 9; lung: 2). A summary from data extracted in each main group of pathologies is

![Flow diagram of the study selection process](image)

**Fig. 1** Flow diagram of the study selection process

![Histogram depicting the number of new studies per year performed with (R)-[11C]PK11195 or all other “challenger” radiotracers](image)

**Fig. 2** Histogram depicting the number of new studies per year performed with (R)-[11C]PK11195 or all other “challenger” radiotracers
provided in Table 1. At individual level, a total of 3914 patients underwent a TSPO PET scan, 47% of those (1851 patients) received (R)-[11C]PK11195. Of the 13 challengers used, 24% (938 patients) had [11C]PBR28, 11% (429 patients) had [18F]FEPPA and 5% (205) had [18F]DPA-714 (Fig. 4). These numbers take in account the re-use of existing experimental groups or cohorts for new analyses (but might be slightly overestimated if new publications do not correctly acknowledge already described datasets). However, it does not take into account healthy controls – a number much more difficult to estimate because of frequent re-use of existing and poorly described cohorts or database. Overall, one in ten patients (11%, 447 patients) underwent a second TSPO scan, whether for a test–retest or longitudinal follow-up with the same radiotracer, or head-to-head comparison between two different radiotracers.

**Discussion on each group of disease**

In this section, we briefly comment on the comparative results from (R)-[11C]PK11195 studies vs challenger studies in the most studied pathologies. Not all included studies are cited in the text. Only the online Zotero database (described in Methods), and the extraction form provided as supplemental material) contains all the 288 papers included. When available, we refer to previously published meta-analysis, reviews or commentaries.

**Neurodegenerative diseases**

**Alzheimer’s disease**

Alzheimer’s disease (AD), and its prodromal condition, mild cognitive impairment (MCI), is the most studied pathology, with a total of 49 publications and 790 patients. It was also one of the first pathology studied apart from glioma, with initial [11C]PK11195 and (R)-[11C]PK11195 reports in patients published in 1995 [30] and 2001 [31]. Among the 8 challengers that have been used for imaging TSPO in MCI/AD, [11C]PBR28 is the mostly used (11 publications, 210 patients). Despite a number of detailed reviews [32–34], no meta-analysis is available yet. Overall recent studies performed with (R)-[11C]PK11195 [35–38] or [11C]PBR28 [39, 40], or [18F]DPA-714 [41, 42] highlight neuro-inflammation as a chronic and biphasic event accompanying amyloid deposition, with a double-edged sword: microglial activation could first be beneficial while turning detrimental in later stages of the disease. But, despite the long disease duration, only 5 publications (3 with (R)-[11C]PK11195 [37, 43, 44] and 2 with challengers [39, 42]) performed longitudinal studies, so this warrants further investigation with more follow-up studies needed to better understand the time-course of neuroinflammation in AD. Most recent studies combined Tau and TSPO imaging, performed with (R)-[11C]PK11195 [37, 45] or challenger radiotracers [46, 47]. From these pioneer studies which used different Tau and TSPO radiotracers, it is however difficult to get a clear
picture about the association between these two biomarkers and their respective prognostic value.

While historically, imaging studies with (R)-[^11]C PK11195 have produced relatively variable results, with some reports showing an increase and some other no change in AD patients vs controls, more recent studies with various challengers such as[^11]C PBR28 [39, 48],[^11]C DPA-713 [49] and[^18]F DPA-714 [41, 42] seem to have produced more consistent finding even across tracers. Now it is actually difficult to conclude on whether this is strictly down to these tracers having better binding characteristics – such as lower non-specific binding, and hence better signal to

| Group | Pathologies (Zotero tags) | Studies with[^11]C PK11195 radiotracer | Studies with challenger radiotracer | Main challenger radiotracer used | Nb studies (patients) |
|-------|---------------------------|----------------------------------------|-----------------------------------|----------------------------------|-----------------------|
|       |                           | Nb of studies (patients)               | Nb of studies (patients) with >1 PET exam/patient | Nb of studies (patients) with >1 PET exam/patient |                        |
| NDD   | Amyloidopathies (MCI/AD)  | 23 (406)                              | 3 (54)                            | 26 (384)                          | 2 (38)                |
|       |                          |            |                                    |[^11]C PBR28: 11 (210)         |                      |
|       | Synucleinopathies (PD/D/DBL/IRBD/MSA) | 20 (218) | 4 (21)                            | 8 (139)                          | 2 (40)                |
|       |                          |            |                                    |[^18]F FEPPA: 4 (59)          |                      |
|       | Tauopathies (FTD/CBD/PSP) | 6 (31)                              | 1 (2)                             | 3 (51)                           | -                    |
|       |                          |            |                                    |[^11]C PBR28: 5 (124)         |                      |
|       | Motor neuron diseases (ALS, PLS) | 3 (23) | -                                 | 8 (144)                          | 1 (10)                |
|       |                          |            |                                    |[^11]C PBR28: 8 (79)         |                      |
|       | Others (HD, CID, FFI)     | 7 (82)                              | -                                 | 1 (8)                            | -                    |
|       |                          |            |                                    |[^11]C PBR28: 5 (124)         |                      |
| DD    | Multiple Sclerosis (MS)   | 19 (316)                              | 6 (72)                            | 20 (213)                         | 7 (39)                |
|       |                          |            |                                    |[^11]C PBR28: 8 (79)         |                      |
|       | Others (X-ALD)            | 1 (1)                              | -                                 | -                               | -                    |
| MD    | Psychosis/Schizophrenia (P/S) | 7 (152) | -                                 | 17 (202)                         | 1 (14)                |
|       |                          |            |                                    |[^18]F FEPPA: 9 (107)         |                      |
|       | Depression and other disorders (D/BD/OCD) | 5 (85) | -                                 | 10 (247)                         | 1 (40)                |
|       |                          |            |                                    |[^18]F FEPPA: 7 (195)         |                      |
|       | Addiction (Add)           | 1 (12)                              | -                                 | 10 (172)                         | -                    |
|       |                          |            |                                    |[^11]C PBR28: 5 (74)         |                      |
|       | Various other neuropsychiatric conditions* | 3 (73) | -                                 | 3 (53)                           | 1 (8)                 |
|       |                          |            |                                    |[^11]C PBR28: 3 (53)         |                      |
|       | HIV-associated dementia (HAD) | 3 (29) | -                                 | 5 (60)                           | -                    |
|       |                          |            |                                    |[^11]C PBR28: 2 (36)         |                      |
|       | Others (HSV, HAM, LD, HCV, HE) | 5 (48) | 1 (2)                             | 2 (19)                           | -                    |
| VD    | Ischemic stroke (IS)      | 11 (79)                              | 6 (34)                            | 5 (30)                           | 2 (14)                |
|       |                          |            |                                    |[^11]C vinpocetine: 2 (10)     |                      |
|       | Others (V, A, ACS, ICH, SVD) | 5 (60) | -                                 | 4 (29)                           | 2 (9)                 |
|       |                          |            |                                    |[^18]F DPA-714: 2 (17)        |                      |
| NO    | Brain tumors (BT)         | 7 (63)                              | -                                 | 11 (94)                          | 1 (1)                 |
|       |                          |            |                                    |[^18]F GE-180: 5 (68)         |                      |
| TBI   | Trauma (T)                | 3 (18)                              | -                                 | 4 (38)                           | 1 (14)                |
|       |                          |            |                                    |[^11]C DPA-713: 3 (23)        |                      |
| Ep    | Epileptic syndromes (E)   | 4 (8)                               | 2 (2)                             | 4 (47)                           | 1 (2)                 |
|       |                          |            |                                    |[^11]C PBR28: 4 (46)         |                      |
| SID   | Rheumatoid arthritis (RA) | 4 (72)                              | 1 (3)                             | 5 (42)                           | 2 (11)                |
|       |                          |            |                                    |[^11]C PBR28: 3 (21)         |                      |
|       | Various other systemic conditions** | 8 (75) | 1 (5)                             | 7 (112)                          | 1 (15)                |
|       |                          |            |                                    |[^11]C PBR28: 6 (102)        |                      |

*a* autoimmune neuropsychiatric disorders, Gulf war illness, post-traumatic stress disorder, attention deficit/hyperactivity disorder, autism

**fibromyalgia; complex regional pain syndrome; lumbar radiculopathy (low back pain); systemic lupus erythematosus; lung diseases; psoriasis; seasonal allergy; peripheral nerve injury; spasms
noise ratio – or better categorisation of the patients recruited (through amyloid scan) or other factors such as improved and more consistent modelling of TSPO PET. Nevertheless, it is encouraging to see recent studies with new tracers showing consistently that neuroinflammation is present at various stage of the disease and helping to progress disease understanding through future longitudinal studies using (R)-[11C]PK11195 challengers [37].

Synucleinopathies

Parkinson’s disease (PD) and other synucleinopathies have been studied in 28 publications and 357 patients, which overall points to a widespread involvement of neuroinflammation. Notably, TSPO imaging was used in 3 studies to monitor treatment effects [50–52], including one phase-2 study in PD performed with [11C]PBR28. Four challengers ([18F]FEPPA [53–55], [11C]PBR28 [52, 56], [11C]DPA-713 [57] and [18F]DPA-714 [58]) were used to image TSPO in synucleinopathies, and all 7 studies involved PD patients. Hence DLB and MSA patients have only been scanned with (R)-[11C]PK11195 yet. In PD, both (R)-[11C]PK11195 [59] and [18F]FEPPA [54] suggested an increase of TSPO binding when patients displayed amyloid co-pathology. Most of the early studies with (R)-[11C]PK11195 in PD reported significant, although modest (approx. +10–25%), increase in microglial activation, mostly located in the basal ganglia [59–64], while Bartels et al. reported a non-significant trend in PD patients vs controls [50]. Interestingly, a very recent (R)-[11C]PK11195 study conducted in at-risk subjects (glucocerebrosidase gene mutation carriers without PD) detected neuroinflammation in brain regions susceptible to Lewy pathology [65].

In other conditions, such as idiopathic rapid-eye-movement sleep behaviour disorder, which patients will ultimately develop a synucleinopathy, Stokholm et al. showed an increase in (R)-[11C]PK11195 BFND in the left substantia nigra and occipital lobe, but not in the basal ganglia [66] or thalamus [67]. Similarly, Surendranathan et al. [68] showed elevated (R)-[11C]PK11195 BPND in dementia with Lewy body patients with mild symptoms vs healthy controls, while patients with severe symptoms were not different from healthy controls, thus suggesting that it is an early event. Furthermore, neuroinflammation was found to correlate with white-matter changes (in the same cohort [69]), and with Tau deposition (in a pilot study [70]). In multiple system atrophy, a severe form of synucleinopathy with a Parkinsonian syndrome, Dodel et al. showed that (R)-[11C]PK11195 BPND was significantly reduced by minocycline treatment although without symptoms improvement [51]. More recently and in the same pathology, Kübler et al. have shown a significant increase in (R)-[11C]PK11195 BPND in basal ganglia and various cortical regions [71]. In most of these studies using (R)-[11C]PK11195, the presence of microglial activation seems pretty unanimous in synucleinopathies.

In contrast, in the studies using the (R)-[11C]PK11195 challenger [18F]FEPPA, Koshimori et al. [72] and Ghadery et al. [53] showed that only the TSPO polymorphism rs6791 had a significant impact on uptake in both healthy controls and PD patients but could not detect any significant difference between controls and PD subjects; results that are in agreement with a more recent study using [11C]PBR28 [56]. However, in a subsequent study [54], in which
Ghadery et al. included an amyloid scan with $^{11}$CPIB, they found no significant differences between controls and PD in PIB-negative subjects, whereas PIB-positive PD patients had increased $^{18}$FPEPPA $V_T$ in several brain regions, suggesting a potential interaction between Aβ deposition and neuroinflammation in PD. Those studies with $^{18}$FPEPPA and $^{11}$CBR28 are in contrast with those obtained with $^{11}$CDA-713 [57] and $^{18}$FDPA-714 [58], who showed significant BPND increases in numerous brain regions in PD patients vs healthy controls, with further increase in a follow-up scan 1 year later [57]. Overall, those studies with (R)-$^{11}$CPK11195 challengers in synucleinopathies are highlighting the potential issues brought by some tracers whose binding is sensitive to the rs6791 polymorphism in complex diseases with moderate and widespread neuroinflammation, harder to detect than in focal brain injuries. Altogether, these results warrant further investigations to better understand the role and time-course of neuroinflammation in synucleinopathies and to determine which tracers perform the best in such challenging situation.

### Tauopathies

Fronto-temporal dementia (FTD) was examined only in pilot studies (4 studies with ≤5 patients each), performed with (R)-$^{11}$CPIK11195 [73, 74], $^{11}$CDA1106 [75] and $^{11}$CBR28 [76]. In brief, Cagnin et al. [73] first showed strong increases in (R)-$^{11}$CPIK11195 BPND in the putamen, hippocampus and dorsolateral frontal cortex. Bevan-Jones et al. [74] later showed similar changes, although in a single patient with microtubule associated protein tau (MAPT) mutation, in the left lateral anterior temporal lobe and bilaterally in the fusiform gyrus. Interestingly, their results suggested that (R)-$^{11}$CPIK11195 PET was better at discriminat- ing MAPT mutation carrier from controls than Tau protein aggregation measured by $^{18}$FAV-1451 PET, highlighting an early role for neuroinflammation at the pre-symptomatic stage of the disease. In a more recent study in patients with frontotemporal dementia with parkinsonism linked to chromosoma 17 (FTDP-17), Miyoshi et al. [75] showed inho- mogeneous increases in $^{11}$CDA1106 uptake in brain regions varying from patient to patient (n = 3). Finally, Kim et al. [76] showed that $^{11}$CBR-28 $V_T$ were significantly increased in frontal, lateral, temporal, parietal, and occipital cortices of FTD patients vs controls.

Other taupathies (corticobasal degeneration, progressive supranuclear palsy) were studied with (R)-$^{11}$CPIK11195 (4 publications, 25 patients [77–80]), and in one very recent study with $^{18}$FGE-180 (combining 30 CBD and 14 PSP [81]). All studies reported a consensual increased binding in the striatum (CBD and PSP) and cortical areas (CBD > PSP).

### Huntington’s disease (HD)

All 6 publications available (77 patients in total) but one used (R)-$^{11}$CPIK11195. The single $^{11}$CBR28 study confirmed a marked increase in the striatum of HD patients, and successfully distinguished patients from controls at the individual level upon principal component analysis [82].

### Prion diseases

A single research group published two (R)-$^{11}$CPIK11195 reports that showed increased TSPO with varying patterns across subtypes of Creutzfeld-Jakob disease [83] or Fatal Familial Insomnia [84]. There is no report using other radiotracers.

### Motor neuron diseases

Motor neuron diseases are a group of neurological disorders with progressive loss of motor neurons which includes amyotrophic lateral sclerosis and primary lateral sclerosis. Of the 11 publications available, most enrolled patients with amyotrophic lateral sclerosis (ALS), but 3 recruited patients with primary lateral sclerosis (PLS). The main challenger was $^{11}$CPIK11195 (5 publications, 124 patients). All studies corroborated an increase in TSPO radioligand uptake which was not restricted to anatomically relevant motor regions and was related to the clinical phenotype (bulbar onset vs limb onset). In the first study with (R)-$^{11}$CPIK11195, Turner et al. [85] showed a significant increase in BPND in motor regions but also in non-motor regions such as frontal lobe, pons and thalamus, with anatomical pathways between motor cortices and those non-motor brain regions likely to explain these changes. Two studies have been performed with $^{18}$FDPA-714 which showed consistent increases in motor cortices of ALS patients vs controls [86, 87]. In a subsequent study, Van Weehaeghe et al. [88] pooled data from their own study using $^{18}$FDPA-714 and data from a $^{11}$CBR28 study [89] in ALS study and confirmed increases in SUVR for both tracers. This suggests that data from different studies with different TSPO tracers using standardised analysis could be gathered, at least in ALS patients, for larger group analysis. In the 4 studies using $^{11}$CBR28 [89–92], there was overall consensus of significant increases in tracer uptake in ALS patients vs controls, although brain regions affected varied slightly from one study to the another, with no further increase at 6 month in follow-up scans being reported by Alshikho et al. [91]. One recent study focused on familial ALS and recruited symptomatic and asymptomatic carriers (SOD1...
Multiple sclerosis (MS)

MS is the most widely studied pathology after AD, with a total of 39 publications and 529 patients. Despite this large amount of data, no meta-analysis has been conducted yet. However, a narrative review was published in 2018 and included 23 studies [94]. The contribution of TSPO PET in MS was also recently tackled in a “Controversies” section of the Multiple Sclerosis Journal [95]. Importantly, it is the only disease for which a significant number of patients (around 20%) underwent two scans (6 studies with (R)-[11C]PK11195, 7 with challengers). These included longitudinal studies [96], monitoring treatment effects [97–101], test–retest studies [102–104], but also rarely performed designs like head-to-head comparisons of tracers in the same patients [20, 29], and a blocking study with the non-radioactive TSPO ligand XBD173 to measure non-displaceable binding of radiotracers [105]. Eight challengers have been used in MS, the main one being [11C]PBR28 (8 publications, 79 patients). Diffuse neuroinflammation, involving normal-appearing white matter and possibly grey matter, was noted in early reports with (R)-[11C]PK11195 [106, 107] and more precisely assessed with challengers [108]. The general idea is that TSPO PET unmasks active lesions and thus reveals hidden but ongoing MS pathology not necessarily revealed by MRI. Indeed, TSPO PET pointed out the heterogeneity of gadolinium-negative lesions, thus leading to a PET-derived classification (active/inactive) of chronic lesions or black holes [103, 109]. Diffuse neuroinflammation in normal appearing white-matter and in normal appearing grey matter, was more pronounced in progressive MS than in relapsing–remitting phenotypes [94]. Several studies pointed out the predictive value of TSPO PET ((R)-[11C]PK11195 [110, 111], [11C]PBR28 [112], [18F]DPA-714 [113]). Overall, in spite of the complexity brought by the different MS subtypes, results from (R)-[11C]PK11195 and challenger studies were in accordance. Importantly, both (R)-[11C]PK11195 and challengers were able to track treatment effects, as shown in studies with Fingolimod, the first oral disease-modifying therapy developed for MS [97, 99].

No other demyelinating condition has been explored to date, except a paediatric case report of X-linked adrenoleukodystrophy, scanned with (R)-[11C]PK11195 [114].

Mental disorders

Psychosis/Schizophrenia (P/S)

This is the most widely studied psychiatric disorder (24 publications, 354 patients), but a single longitudinal study has been reported to date (performed with [11C]PBR111 [115]). Importantly, the results in this field have been abundantly discussed in one review published in 2017 (which included 11 studies, performed with (R)-[11C]PK11195 and challengers [116], followed by two meta-analysis—one conducted on all TSPO radiotracers (12 studies [117]), and one restricted to challengers (5 studies [118])—which yielded opposite conclusions. The latter found strong evidence of lower levels of TSPO in patients, which could correspond to altered function or lower density [118]. The former found an increase of TSPO PET tracer binding in patients, only when non-displaceable binding potential BPND (mainly used in (R)-[11C]PK11195 studies) was used as an outcome measure. When tracer volume of distribution VT was used (mainly in challenger studies), the difference was absent [117]. The interpretation of these heterogeneous results is not straightforward, and various sources of biological variation have been put forward (medication, sub-group differences), in addition of PET methodological considerations [119]. While specific recommendations for future TSPO studies in P/S have been proposed [119], including the need to perform longitudinal studies, others questioned the specificity of TSPO (through post-mortem evaluation of TSPO densities) and call for new neuroinflammation targets to be explored [120].

Depression

Patients with major depressive disorder were enrolled in 11 studies, performed with (R)-[11C]CPK11195 [121–123] or [18F]FEPPA [124–129] or [11C]PBR28 [130, 131]. Six of them were included in a meta-analyse [132], showing a most-pronounced increase in anterior cingulate cortex and hippocampus. Overall, the studies pointed out the potential involvement of two other regions, namely the frontal cortex and the insula. A cross-sectional study published by Setiawan et al. in the Lancet Psychiatry convincingly demonstrated using [18F]FEPPA that VT was significantly higher in patients with major depressive disorder untreated for a long period compared to those untreated for a short period of time [127]. Thus, they suggested that the increase of microglial activation over the curse of the disease was disrupted by antidepressant treatment. Two other [18F]FEPPA studies were used in conjunction with non-pharmacological (psychotherapy [126]) and pharmacological (celexobix [128]) treatments. These studies respectively reported that when cognitive-behavioural therapy efficiently reduced the symptoms, it also reduced [18F]FEPPA VT, and that
Celecoxib therapy was effective only in patients with high $[^{18}F]$FEPPA $V_T$ values in frontal cortex and anterior cingulate cortex [128]. Though $[^{18}F]$FEPPA was successfully used in several large studies, the only study performed with $(R)$-$[^{11}C]$PK11195 (along with a pilot report [121]) revealed the same results in the anterior cingulate cortex (with a relatively high effect size), whereas the effects were less pronounced in the frontal cortex and the insula [122]. Importantly, these conclusions have been very recently confirmed in a new, large cohort of 51 patients scanned with $(R)$-$[^{11}C]$PK11195 [123, 133].

One $[^{11}C]$PBR28 study enrolled healthy subjects exposed to psychosocial risk factors (and therefore at risk of depression or psychosis) and found no difference with an unexposed, group [134].

**Addiction**

TSPO PET studies on addiction disorders include a single $(R)$-$[^{11}C]$PK11195 report published in 2008 [135], and 10 more recent publications performed with 3 different challenges ($[^{11}C]$PBR28 [136–140], $[^{11}C]$DA11106 [141–143], $[^{18}F]$FEPPA [144, 145]). Results were highly dependent on i) addiction subtypes (i.e. methamphetamine users, alcohol-dependent, cigarette smokers, cannabis smokers, …), ii) patient state (active user vs abstinent), and iii) experimental design (e.g. time between last exposition and PET scanning). Longitudinal data are awaited to understand the relationship between chronic use and TSPO density.

**Other mental disorders**

Sparse data are available for various other psychiatric illnesses: bipolar disorder (2 publications using the same cohort scanned with $(R)$-$[^{11}C]$PK11195 [146, 147]); obsessive–compulsive disorder (2 publications using $[^{18}F]$FEPPA [129, 148]); a single $(R)$-$[^{11}C]$PK11195 study on adults with attention deficit/hyperactivity disorder [149]; single studies on post-traumatic stress disorder [150] and Gulf war illness [151], both using $[^{11}C]$PBR28; one $(R)$-$[^{11}C]$PK11195 publication dedicated to children with autoimmune neuropsychiatric disorders (associated with streptococcal infection, and Tourette syndrome) [152]; and 2 studies ($(R)$-$[^{11}C]$PK11195 [153] and $[^{11}C]$PBR28 [154]) on young autistic adults, which yielded opposite results. While the $(R)$-$[^{11}C]$PK11195 study found higher BP values in multiples regions and especially in the cerebellum, the $[^{11}C]$PBR28 study reported decreased SUVR in several regions and no region with higher SUVR than controls. The $(R)$-$[^{11}C]$PK11195 study used dynamic scans, and, unusually the cerebellum from controls was used as reference region for the simplified reference tissue model in the patients. The $[^{11}C]$PBR28 study used static scans and whole brain mean normalisation for SUVR calculations.

Decreased TSPO densities are difficult to interpret: it might be related to a physiological role of TSPO, and could be the case of autism reveal mitochondrial dysfunction, as suggested by the authors [154].

**4.4 Encephalopathies and viral infections**

**HIV-associated dementia.** It has been hypothesized that microglial activation could be responsible for the cognitive impairments found in some HIV-positive patients despite effective antiviral treatment. Initial $(R)$-$[^{11}C]$PK11195 studies yielded inconsistent results, with an increase of TSPO radiotracer binding being detected [155, 156] or not [157]. Similarly heterogeneous results were obtained with $[^{11}C]$PBR28 [158, 159], so no conclusion can be drawn on the role of neuroinflammation in AIDS, as recently reviewed [160].

Others viral infections explored included: Lyme disease with $(^1C)$DPA-713 [161]; *Herpes simplex encephalitis* with $(R)$-$[^{11}C]$PK11195 [162]; *hepatitis C* with $(R)$-$[^{11}C]$PK11195 [163, 164] and *T-lymphotropic virus Type I* with $(^{11}C)$PBR28 on associated myelopathy [165].

Finally, two $(^{11}C)$PK11195 reports in hepatic encephalitis in (< 10) cirrhotic patients yielded different results, one (using the R-enantiomer) finding increased uptake in comparison to controls [166], but not the other (using the racemic radiotracer) [167].

**Ischemic stroke and other vascular diseases**

Most stroke studies were performed with $(R)$-$[^{11}C]$PK11195 (11 publications on ischemic stroke, one publication on haemorrhagic stroke [168], 84 patients in total). Ten stroke patients were scanned with $(^{11}C)$vinpocetine, among which 4 back-to-back with $(R)$-$[^{11}C]$PK11195 [25, 169] and 9 patients with $(^{18}$F)DPA-714 [170]. In addition, one recent study directly compared $(R)$-$[^{11}C]$PK11195 and $(^{18}$F)GE-180 in the same 10 patients at the sub-acute stage (< 1 month), and discarded the use of the latter because of poor brain uptake and strong contribution of vascular signals [26]. Few patients (< 20 in total) were scanned at the chronic stage, up to 5–6 months after stroke onset [171, 172]. The late TSPO changes in the area of the primary lesion, but also in areas distant from the primary lesion site, probably deserve to be explored further, as they might play a role in either recovery or indicate long-term distal retrograde degeneration.

One recent study focused on small vessel disease and highlighted increased, mostly vascular, $(^{11}C)$PBR28 binding in white matter hyperintensities [173].

Peripheral imaging was performed to study *atheroma* (one $(R)$-$[^{11}C]$PK11195 report [174]), *acute coronary syndrome* (one $(^{18}$F)DPA-714 report [175]), and *vasculitis* (two $(R)$-$[^{11}C]$PK11195 reports [176, 177]). The latter pathology...
was recently imaged, this time at the brain level, with $[^{18}\text{F}]$ DPA-714 [178].

**Traumatic Brain Injury (TBI)**

Relatively few studies investigated the long-term neuroinflammation after trauma (3 $(R)$-$[^{11}\text{C}]$PK11195 publications [179–181], 4 with challengers [182–185]). Severity varied greatly with aetiology, making inter-study comparison perilous. Overall, studies agreed on the fact that TBI triggered a chronic inflammatory response particularly in subcortical regions, with a specific involvement of the thalamus. $[^{11}\text{C}]$ DPA-713 was used in the specific context of chronic traumatic encephalopathy (CTE), a recently diagnosed disease described in American football players [182, 183]. Localized brain injury and repair, indicated by increased $[^{11}\text{C}]$DPA-713 uptake, may be linked to history of football-related repeated traumatic brain injuries, although further studies are needed to determine whether TSPO signals in CTE are related to later onset of neuropsychiatric symptoms or altered functional connectivity [185]. Interestingly, in an pilot clinical trial involving patients with moderate-to-severe TBI, minocycline treatment reduced chronic microglial activation as assessed with $[^{11}\text{C}]$PBR28, but increased a plasma marker of neurodegeneration [184]. The lack of similar study with $(R)$-$[^{11}\text{C}]$PK11195 precludes any formal comparison although one study revealed a thalamic TSPO increase up to 17 years after TBI [180].

**Neuro-oncology**

Brain tumours were studied in 7 publications with $(R)$-$[^{11}\text{C}]$PK11195 and 11 publications with challengers. This includes the oldest reports of TSPO imaging in humans, performed with $[^{11}\text{C}]$Ro5-4864 [8, 186], a radiotracer which was abandoned for $[^{11}\text{C}]$PK11195. Six other publications are case reports. So in fact this field remains relatively unexplored, and longitudinal studies are lacking (2 $[^{11}\text{C}]$PBR28 scans were performed in a single case report of astrocytoma [187]). The different studies, with either $(R)$-$[^{11}\text{C}]$PK11195 or challengers, reported specific binding of TSPO radioligands by tumour cells thereby pointing to the difficult discrimination between reactive neuroinflammation and tumour development itself [188]. This is clearly illustrated by studies using the challengers $[^{18}\text{F}]$GE-180 [189] and $[^{18}\text{F}]$DPA-714 [190] along with amino-acid radiotracer ($[^{18}\text{F}]$Fluoro-ethyl-tyrosine), which showed diverging spatial extent of the different radiotracers. These results highlighted the heterogeneity of the immune tumour microenvironment on one hand, and on the other hand, the fact that neuroinflammation may not overlap with tumour proliferation. As another example of this caveat, neuroinflammation in the context of brain metastases was recently reported in 5 cases of non-small cells lung carcinoma and melanoma brain metastases [191], but $[^{11}\text{C}]$ PBR28, in contrast to $[^{11}\text{C}]$methionine, could not differentiate metastatic tumour recurrence from neuroinflammation-induced radiation necrosis.

**Epileptic disorders**

Epileptic syndromes may have a variety of aetiologies. Some cases of Rasmussen’s encephalitis and hippocampal sclerosis were studied with $(R)$-$[^{11}\text{C}]$PK11195 [12]. Few other studies were performed in temporal lobe epilepsy [28, 192], neurocysticercosis [193], and neocortical epilepsy [194] using $[^{11}\text{C}]$PBR28 or $[^{11}\text{C}]$DPA-713. Apart from the neurocysticercosis cases, in which acute perilesional oedema caused the inflammation revealed by TSPO uptake, all studies agreed on a clear asymmetry of PET signals with increased uptake in the hemisphere ipsilateral to the seizure foci, despite frequent involvement of bilateral regions. Interestingly, the computed asymmetry index was higher in patients suffering from mesial temporal sclerosis. Considering the low number of studies, and the lack of direct head-to-head comparison between $(R)$-$[^{11}\text{C}]$PK11195 and challengers, it is difficult to conclude on the added value of such tracers. However, the pioneer $(R)$-$[^{11}\text{C}]$PK11195 study by Banati et al. [12] did not find a lateralized increase of binding in 3 patients with temporal lobe epilepsy (TLE), in contrast to Rasmussen’s encephalitis [12] and refractory epilepsy [195] imaged with $(R)$-$[^{11}\text{C}]$PK11195, and in contrast to further $[^{11}\text{C}]$PBR28 [28, 192–194] or $[^{11}\text{C}]$DPA-713 [28] studies in TLE. While this could be due to low seizure frequency in this clinically-stable patients, one might also hypothesize that $[^{11}\text{C}]$PK11195 lacked sensitivity to catch a modest TSPO increase in epilepsy.

**Systemic inflammatory diseases**

**Rheumatoid arthritis (RA)**

TSPO PET allowed the detection of active clinical but also subclinical synovitis in joints (knees, wrists, hands). After 3 initials $(R)$-$[^{11}\text{C}]$PK11195 studies which used a short static scan and scoring scale to assess overall uptake on multiple joints [196–198], there was a renewed interest in this pathology driven by the use of various challengers and SUV quantification [27, 199–201]. In one study, head-to-head comparisons of 3 radiotracers provided a clear demonstration of increased target-to-background ration with $[^{11}\text{C}]$ DPA-713 [27]. Successful blocking of $[^{11}\text{C}]$PBR28 binding with XBD173 was reported very recently [201]. Finally, the involvement of the brain immune system in RA was recently explored with $[^{11}\text{C}]$PBR28 [202], but no differences in TSPO binding were detected in RA vs controls.
Other systemic inflammatory diseases

Several other inflammatory diseases were explored in pioneer studies: fibromyalgia [2 publications, with (R)-\(^{[18F]}\)PK11195 [203] and \(^{[11C]}\)PBR28 [204]; lumbar radiculopathy usually referred as chronic low back pain (4 publications with \(^{[11C]}\)PBR28 [205–208]); type 1 complex regional pain syndrome (2 publications on the same cohort with (R)-\(^{[11C]}\)PK11195 [209, 210]); lung diseases (2 publications with (R)-\(^{[11C]}\)PK11195 [211, 212]); as well as systemic lupus erythematosus [213], psoriasis [214], seasonal allergy [215], peripheral nerve injury [216], spasms [217].

General discussion

Many excellent narrative reviews on TSPO PET have been published these last few years [218–221], and dozens of critical literature reviews covered more or less extensively this topic in the main diseases with neuroinflammatory component [33], like Alzheimer’s disease [34, 222] or multiple sclerosis [94]. We here performed the first systematic search and review on clinical applications of TSPO PET. By assessing the total number of studies and patients (and taking in account the re-use of cohorts), we provided a quantitative overview of the wide field of neuroinflammation imaging. This is a timely achievement to question the impact of (R)-\(^{[11C]}\)PK11195 challengers as most studies with these so-called second-generation tracers were performed in the last 5 years (Fig. 2).

In total, 13 challengers were used to scan patients, 4 of which had a marginal use. First, \(^{[11C]}\)Ro5-4864 was developed along with \(^{[11C]}\)PK11195 and was abandoned after 2 pilot neuro-ontology studies in the 80’s [8, 186]. Second, a pathophysiological uptake of \(^{[11C]}\)CB184 was described in a single case report of cerebellar ataxia associated with HIV infection [223]. Finally, the use of \(^{[18F]}\)FEMPA and \(^{[18F]}\)FEDAA1106 was restricted to one and two pilot studies respectively, all performed at the Karolinska Institute (Stockholm, Sweden) [224–226]. Two other radiotracers were used in several studies or pathological conditions, but emanated from a single research centre. This is the case of \(^{[18F]}\)PBR06 (3 publications in MS patients [29, 227, 228] performed at Harvard Medical School, Boston, USA) and \(^{[11C]}\)vinpocetine (4 publications in AD [229], MS [20] and stroke [25, 169] patients, all performed at the Karolinska Institute. In the case of \(^{[18F]}\)PBR111, two independent research groups conducted studies in multiple sclerosis [103, 230, 231] (Imperial College London, UK) and schizophrenia/psychosis [115, 232] (University of Antwerp, Belgium). Among the 6 remaining challengers, 2 were restricted to specific groups of pathologies: \(^{[11C]}\)DAA1106 and \(^{[18F]}\)FEPPA were used only in neurodegenerative diseases and mental disorders ([11C]DAA1106: 20 and 91 patients respectively; \(^{[18F]}\)FEPPA: 77 and 337 patients respectively), \(^{[18F]}\)GE-180, initially mainly used in patients with multiple sclerosis (45 patients) and brain tumour (68 patients), was recently tested in other pathologies (tauopathies [81], rheumatoid arthritis [200] and stroke [26]). However, \(^{[18F]}\)GE-180 was shown to have slow/poor brain uptake in human [233], and the consequences on quantification and modelling have abundantly debated [234–236]. Finally, only \(^{[11C]}\)PBR28 covered the 9 disease groups (938 patients in total), \(^{[11C]}\)DPA-713 (7 disease groups) and \(^{[18F]}\)DPA-714 (5 disease groups) were also widely used but cumulated a much lower number of patients (143 and 205 respectively).

Interestingly the main challenger, \(^{[11C]}\)PBR28, shares with (R)-\(^{[11C]}\)PK11195 the disadvantage of a carbon-11 labelling, thereby limiting its availability. Hence to date, fluorinated radiotracers for TSPO, like \(^{[18F]}\)DPA-714 and \(^{[18F]}\)FEPPA, remained under-used in comparison to \(^{[11C]}\)PBR28 and \(^{[11C]}\)PK11195. Despite displaying higher affinity and specific binding than \(^{[11C]}\)PK11195, \(^{[11C]}\)PBR28 has the disadvantage of being highly sensitive to the human Ala147Thr polymorphism [237] because of its strong affinity for the high-affinity binding site, an issue that might discourage research groups working with (R)-\(^{[11C]}\)PK11195 from switching to another radiotracer. This human polymorphism, along with specific blood–brain characteristics different from animals, as highlighted in the case of \(^{[18F]}\)GE-180 in stroke [26, 238], further emphasizes the need for rapid translation from animal model to human to thoroughly validate radiotracers. Despite the increasing number of challengers entering clinical evaluation, (R)-\(^{[11C]}\)PK11195 studies have been constantly accumulating over the last twenty years, with no trend of disinterest. This is in itself a sign that this historical TSPO tracer has not been outclassed by any of the challengers yet although the number of studies using challengers per annum has now surpassed the number of (R)-\(^{[11C]}\)PK11195 studies. One straightforward reason is that (R)-\(^{[11C]}\)PK11195 is insensitive to the TSPO polymorphism. However this situation is expected to change in the near future as some of the newly developed (R)-\(^{[11C]}\)PK11195 challengers, sometimes called third-generation tracers, currently being evaluated in animal models and in healthy human subjects, were successfully tested as insensitive or less sensitive to TSPO polymorphism in humans: \(^{[18F]}\)LW223 [239]; \(^{[18F]}\)CB251 [240]; \(^{[11C]}\)ER176 [241]. The latter was suggested to have very favourable properties in healthy subjects, being sensitive enough to detect specific binding in low-affinity binders, with little influence of radiometabolites [242]. Therefore, we can anticipate that the coming years will be crucial for TSPO imaging as these new challengers will be tested in patients.

Overall, the multiplicity of tracers in preclinical studies has translated in multiple, clinical studies with various
radiotracers. Owing to the inherent difficulties and debates about the modelling of TSPO PET data, it is difficult to draw conclusions and identify an area with a clear added-value of challengers, despite their predicted superiority [243]. In this review we could however identify the following pathologies in which challengers were efficient in strengthening initials results suggested by (R)-[11C]PK11195 studies and/or in renewing an interest in TSPO imaging: Alzheimer’s and Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, rheumatoid arthritis. In most cases, challengers brought confirmation of (R)-[11C]PK11195 results, rather than true novelty. One particular case is the field of psychiatric diseases, in which the number of studies performed with challengers is notably higher than the number of (R)-[11C]PK11195 studies (40 vs 16). This led to concordant results (in the case of depression), or apparently conflicting results (in the case of psychosis/schizophrenia). We did not identify any proper replication study (similar experimental groups, similar quantification methods) performed with (R)-[11C]PK11195 and another radiotracer. This point deserves peculiar attention as replication studies would be a clear asset to investigate the potential benefits of challenger TSPO PET radiotracers over (R)-[11C]PK11195. More generally, replication studies are cruelly lacking in biomedical sciences, and sciences agencies start to handle this problem with dedicated funds [244]. Hence, cornerstone studies on TSPO PET imaging would definitely benefit from replication. Finally, of particular importance are rare but highly-informative reports such as i) blocking studies with newly approved TSPO ligands like XBD173 [105, 201, 242], ii) double-tracer studies (12 records).

A striking feature of this systematic review is the very weak proportion of longitudinal studies. Our 11% count pooled test–retest studies and multiple-tracer studies so the real proportion of patients who underwent a follow-up scan is even below. This is paradoxical as TSPO PET is often promoted for its ability to dynamically track inflammation changes over time. However, this weakness may be justified by the significant proportion of studies in which TSPO PET scan was associated with another radiotracer (e.g. [11C]PIB in Alzheimer, [18F]FET in tumours) hence adding a dosimetry issue for the management of longitudinal studies. Another reason is probably the rarely-studied, high (and method-dependent) intra-subject variability which complicates longitudinal monitoring of TSPO changes [102, 245–247]. This last point, together with the poor specificity of TSPO expression (whether it be for a cell type or a type of activation [120, 248]) might ultimately questions the utility of developing so many tracers for the very same target. In that view, back-to-back comparison between TSPO and another inflammatory target (as performed in the case of P2X7 [87]) is of utmost importance for the validation of new clinically-relevant radiotracers. As metabolic changes of senescent myeloid cells are being deciphered [249], new original targets may help to identify and ultimately prevent maladaptive pro-inflammatory responses.

We propose this contribution as the first version of a living review on TSPO PET in the clinics. Living reviews are regularly updated to reflect emerging trends or evidence [250]. With version 2 planned at the beginning of year 2023 (covering 2021–22 years), we will address limitations of the current work and provide timely information for the design of future studies, that is:

- multi-database search to include, in addition to PubMed records, conference proceedings, preprint publications and registered trials, with the goal to better catch ongoing research, as new challengers are to enter the arena;
- include normal aging studies and pharmacological challenges (LPS, XBD-173) performed in healthy controls, which were excluded at this stage but bring important information;
- provide online infographic summaries of clinical TSPO PET studies, possibly interactive, based on the figures presented here.

Acknowledgements This work was performed within the framework of the LABEX PRIMES (ANR-11-LABX-0063) of Université de Lyon, within the program “Investissements d’Avenir” (ANR-11-IDEX-0007) operated by the French National Research Agency (ANR).

Funding GB was supported by a grant from the French National Research Agency (ANR-15-CE17-0020).

Availability of data and material All data generated or analysed during this study are included in this published article and its supplementary information files.

Code availability not applicable.

Declarations

Competing interests HB received funding from GSK but GSK was not involved in the writing of any part of this review. FC declares that he has no conflict of interest. GB declares that he has no conflict of interest.

Ethical approval This article does not contain any studies with human participants performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated
References

1. Benavides J, Quarteronet D, Imbault F, et al. Labelling of “peripheral-type” benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: kinetic studies and autoradiographic localization. J Neurochem. 1983;41:1744–50.

2. Benavides J, Guilloux F, Rufat P, et al. In vivo labelling in several rat tissues of “peripheral type” benzodiazepine binding sites. Eur J Pharmacol. 1984;99:1–7.

3. Papadopoulos V, Baraldi M, Guiltarte TR, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402–9.

4. Benavides J, Fage D, Carter C, et al. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res. 1987;421:167–72.

5. Benavides J, Capdeville C, Dauphin F, et al. The quantification of brain lesions with an omega 3 site ligand: a critical analysis of animal models of cerebral ischaemia and neurodegeneration. Brain Res. 1990;522:275–89.

6. Camsonne R, Crouzel C, Comar D, et al. Synthesis of N-[(11C) methyl, N-(methyl-1 propyl), (chloro-2 phenyl)-1 isoquinoline carboxide-3 (PK 11195): A new ligand for peripheral benzodiazepine receptors. J Label Compd Radiopharm. 1984;21:985–91.

7. Pappata S, Cornu P, Samson Y, et al. PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report. J Nucl Med Off Publ Soc Nucl Med. 1991;32:1608–10.

8. Bergström M, Mosskin M, Ericson K, et al. Peripheral benzodiazepine binding sites in human gliomas evaluated with positron emission tomography. Acta Radiol Suppl. 1986;369:409–11.

9. Stephenson DT, Schober DA, Smaistl EB, et al. Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J Neurosci. 1995;15:5263–74.

10. Banati RB, Myers R, Kreutzberg GW. PK (‘peripheral benzodiazepine’)—binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK 11195 binding to activated microglia. J Neurol. 1997;267:77–82.

11. Vowinckel E, Reutens D, Becher B, et al. PK 11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res. 1997;50:345–53.

12. Banati RB, Goeres GW, Myers R, et al. [11C](R)-PK 11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen’s encephalitis. Neurology. 1999;53:2199–203.

13. Coenen HH, Gez AD, Adam M, et al. Consensus nomenclature rules for radiopharmaceutical chemistry — Setting the record straight. Nucl Med Biol. 2017;55:v–xi.

14. Favre HA, Powell WH. Nomenclature of Organic Chemistry. 2013.

15. Cagnin A, Gerhard A, Banati RB. The concept of in vivo imaging of neuroinflammation with [11C](R)-PK 11195 PET. Ernst Scher Res Found Workshop 2002;179–91.

16. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006;80:308–22.

17. Chauveau F, Boutin H, Van Camp N, et al. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK 11195 challenges. Eur J Nucl Med Mol Imaging. 2008;35:2304–19.

18. Zhang L, Hu K, Shao T, et al. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta Pharmac Sin B. 2021;11:373–93.

19. Yasuno F, Ota M, Kosaka J, et al. Increased Binding of Peripheral Benzodiazepine Receptor in Alzheimer’s Disease Measured by Positron Emission Tomography with [11C]DAA1106. Biol Psychiatry 2008;64:835–841. https://doi.org/10.1016/j.biopsych.2008.04.021.

20. Vas A, Shchukin Y, Karrenbauer VD, et al. Functional neuroimaging in multiple sclerosis with radiolabelled galaxa markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK 11195 in patients. J Neurol Sci. 2008;264:9–17.

21. Cumming P, Burgher B, Patkar O, et al. Sifting through the surf–fein of neuroinflammation tracers: J Cereb Blood Flow Metab 2018;38:204–224.

22. Chang S. Scoping Reviews and Systematic Reviews: Is It an Either/Or Question? Ann Intern Med. 2018;169:502–3.

23. Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev. 2021;10:39.

24. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–73.

25. Gulyas B, Toth M, Vas A, et al. Visualising neuroinflammation in post-stroke patients: a comparative PET study with the TSPO molecular imaging biomarkers [11C]PK 11195 and [11C]vinpocetine. Curr Radiopharm. 2012;5:19–28.

26. Visi E, Hinz R, Punter M, et al. Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study. Southampton (UK): NIHR Journals Library; 2020.

27. Bruijnjen STG, Verweij NJF, Gent YYJ, et al. Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracers. PLoS ONE. 2019;14:e0222844.

28. Gershon LD, Zanotti-Fregonara P, Dustin IH, et al. Neuroinflammation in Temporal Lobe Epilepsy Measured Using Positron Emission Tomographic Imaging of Translocator Protein. JAMA Neurol. 2015;72:882–8.

29. Singhal T, O’Connor K, Dubey S, et al. 18F-PBR28 PET Against White Matter Translocator Protein Binding in Multiple Sclerosis. Clin Nucl Med. 2018;43:e289–95.

30. Groom GN, Junck L, Foster NL, et al. PET of peripheral benzodiazepine binding sites in the microglioss of Alzheimer’s disease. J Nucl Med. 1995;36:2207–10.

31. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461–7.

32. Varrone A, Nordberg A. Molecular imaging of neuroinflammation in Alzheimer’s disease. Clin Transl Imaging. 2015;3:437–47.

33. Dupont A-C, Largeau B, Santiago Ribeiro M, et al. Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. Int J Mol Sci. 2017;18:785.

34. Lagarde J, Sarazin M, Bottlaender M. In vivo PET imaging of neuroinflammation in Alzheimer’s disease. J Neural Transm. 2018;125:847–67.

35. Parbo P, Ismail R, Hansen KV, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease. Brain J Neurol. 2017;140:2002–11.
36. Parbo P, Ismail R, Sommerauer M, et al. Does inflammation precede tau aggregation in early Alzheimer’s disease? A PET study. Neurobiol Dis. 2018;117:211–6.

37. Ismail R, Parbo P, Madsen LS, et al. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study. J Neuroinflammation. 2020;17:151.

38. Parbo P, Madsen LS, Ismail R, et al. Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease. Alzheimers Res Ther. 2020;12:3.

39. Kreisl WC, Lyoo CH, Liow J-S, et al. (11C)PB28 binding to translocator protein increases with progression of Alzheimer’s disease. Neurobiol Aging. 2016;44:53–61.

40. Dani M, Wood M, Mizoguchi R, et al. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer’s disease. Brain J Neurol. 2018;141:2740–54.

41. Hamelin L, Lagarde J, Dorotheé G, et al. Early and protective microglial activation in Alzheimer’s disease: a prospective study using 18F-DPA-714 PET imaging. Brain J Neurol. 2016;139:1252–64.

42. Hamelin L, Lagarde J, Dorotheé G, et al. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer’s disease. Brain J Neurol. 2018;141:1855–70.

43. Fan Z, Okello AA, Brooks DJ, et al. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer’s disease. Brain J Neurol. 2015;138:3685–98.

44. Fan Z, Brooks DJ, Okello A, et al. An early and late peak in microglial activation in Alzheimer’s disease trajectory. Brain J Neurol. 2017;140:792–803.

45. Malpetti M, Kievet RA, Passamonti L, et al. Microglial activation and tau burden predict cognitive decline in Alzheimer’s disease. Brain J Neurol. 2020;143:1588–602.

46. Terada T, Yokokura M, Obi T, et al. In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer’s disease. J Neurol. 2019;266:2186–96.

47. Zou J, Tao S, Johnson A, et al. Microglial activation, but not tau pathology, is independently associated with amyloid positivity and memory impairment. Neurobiol Aging. 2020;85:11–21.

48. Fenninella GD, Dani M, Wood M, et al. Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology. 2019;92:e1331–43.

49. Yokokura M, Terada T, Bunai T, et al. Depiction of microglial activation in aging and dementia: Positron emission tomography with [11C]DPA713 versus [11C](R)-PK11195. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2017;37:877–89.

50. Bartels AL, Willemse ATM, Doorduin J, et al. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson’s disease? Parkinsonism Relat Disord. 2010;16:57–9.

51. Dodel R, Spotte A, Gerhard A, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [11C]-(R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010;25:97–107.

52. Jucaite A, Svenningsson P, Rinne JO, et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease. Brain J Neurol. 2015;138:2687–700.

53. Ghadery C, Koshimori Y, Coakeley S, et al. Microglial activation in Parkinson’s disease using [18F]-FEPPA. J Neuroinflammation. 2017;14:8.

54. Ghadery C, Koshimori Y, Christopher L, et al. The Interaction Between Neuroinflammation and β-Amyloid in Cognitive Decline in Parkinson’s Disease. Mol Neurobiol. 2020;57:492–501.

55. Mabrouk R, Strafella AP, Knezevic D, et al. Feasibility study of TSPO quantification with [18F]FEPPA using population-based input function. PLoS ONE. 2017;12:e0177785.

56. Varnä S, Czelényi Z, Jucaite A, et al. PET imaging of [11C]PBR28 in Parkinson’s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. Eur J Nucl Med Mol Imaging. 2019;46:367–75.

57. Terada T, Yokokura M, Yoshikawa E, et al. Extrastriatal spreading of microglial activation in Parkinson’s disease: a positron emission tomography study. Ann Nucl Med. 2016;30:579–87.

58. Lavisse S, Goutal S, Wimbler C, et al. Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging. Parkinsonism Relat Disord. 2021;82:29–36.

59. Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38:938–49.

60. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol. 2005;57:168–75.

61. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006;21:404–12.

62. Iannaccone S, Cerami C, Alessio M, et al. In vivo microglial activation in very early dementia with Lewy bodies, comparison with Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:47–52.

63. Kobylecki C, Counsell SJ, Cabanel N, et al. Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. Parkinsonism Relat Disord. 2013;19:527–32.

64. Kang Y, Mozley PD, Verma A, et al. Noninvasive PK11195-PET Image Analysis Techniques Can Detect Abnormal Cerebral Microglial Activation in Parkinson’s Disease. J Neuroimaging Off J Am Soc Neuroimaging. 2018;28:496–505.

65. Mullin S, Stokholm MG, Hughes D, et al. Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2021;36:774–9.

66. Stokholm MG, Iranzo A, Østergaard K, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 2017;16:789–96.

67. Stokholm MG, Iranzo A, Østergaard K, et al. Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiol Dis. 2018;115:9–16.

68. Surendranathan A, Su L, Mak E, et al. Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain J Neurol. 2018;141:3415–27.

69. Nicastro N, Mak E, Williams GB, et al. Correlation of microglial activation with white matter changes in dementia with Lewy bodies. NeuroImage Clin. 2020;25:102200.

70. Mak E, Nicastro N, Malpetti M, et al. Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography. Neurobiol Aging. 2020;101:172–80.

71. Kühler D, Wächter T, Cabanel N, et al. Widespread microglial activation in multiple system atrophy. Mov Disord Off J Mov Disord Soc. 2019;34:564–8.

72. Koshimori Y, Ko J-H, Mizrahi R, et al. Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease. PLoS ONE. 2015;10:e0138721.

73. Cagnin A, Rossor M, Sampson EL, et al. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol. 2004;56:894–7.
74. Bevan-Jones WR, Cope TE, Jones PS, et al. In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier. Ann Clin Transl Neurol. 2019;6:373–8.
75. Miyoshi M, Shimoto H, Wsoklew ZK, et al. In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. Parkinsonism Relat Disord. 2010;16:404–8.
76. Kim M-J, McGwier M, Jenko KJ, et al. Neuroinflammation in frontotemporal lobar degeneration revealed by 11 C-PBR28 PET. Ann Clin Transl Neurol. 2019;6:1327–31.
77. Gerhard A, Watts J, Trender-Gerhard I, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Discord. 2004;19:1221–6.
78. Henkel K, Karitzky J, Schmid M, et al. Imaging of activated microglia with PET and [11C]PK11195 in corticobasal degeneration. Mov Discord. 2004;19:817–21.
79. Gerhard A, Trender-Gerhard I, Turkeiher F, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Discord. 2006;21:89–93.
80. Passamonti L, Rodriguez PV, Hong YT, et al. [11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. Neurology. 2018;90:e1989–96.
81. Palleis C, Sauerbeck J, Beyer L, et al. In Vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies. Mov Discord Off J Mov Discord Soc. 2021;36:883–94.
82. Lois C, Gonzalez I, Izquierdo-Garcia D, et al. Neuroinflammation in Huntington’s Disease: New Insights with 11C-PBR28 PET/ MRI. ACS Chem Neurosci. 2018;9:2563–71.
83. Iaccarino L, Morecs-M, Presotto L, et al. An In Vivo 11C-(R)-PK11195 PET and In Vitro Pathology Study of Microglia Activation in Creutzfeldt-Jakob Disease. Mol Neurobiol. 2018;55:2856–68.
84. Iaccarino L, Presotto L, Bettinardi V, et al. An in vivo 11C-PK PET study of microglia activation in Fatal Familial Insomnia. Ann Clin Transl Neurol. 2018;5:11–8.
85. Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15:601–9.
86. Corcia P, Tauber C, Vercoullie J, et al. Molecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis. PLoS ONE. 2012;7:e52941.
87. Van Weeheghaeghe D, Van Schoor E, De Vocht J, et al. TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study. J Nucl Med Off Publ Soc Nucl Med. 2020;61:604–7.
88. Van Weeheghaeghe D, Babu S, De Vocht J, et al. Moving towards multicenter therapeutic trials in ALS: feasibility of data pooling using different TSPO positron emission tomography (PET) radioligands. J Nucl Med Off Publ Soc Nucl Med 2020;61(11):1621–1627.
89. Zürcher NR, Loggia ML, Lawson R, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuro Image Clin. 2015;7:409–14.
90. Alsheikho MJ, Zürcher NR, Loggia ML, et al. Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology. 2016;87:2554–61.
91. Alsheikho MJ, Zürcher NR, Loggia ML, et al. Integrated magnetic resonance imaging and [(11)C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol. 2018;83:1186–97.
92. Ratai E-M, Alsheikho MJ, Zürcher NR, et al. Integrated imaging of [(11)C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy 1H-MRS in amyotrophic lateral sclerosis. Neuro Image Clin. 2018;20:357–64.
93. Tondo G, Iaccarino L, Cerami C, et al. 11 C-PK11195 PET-based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2020;7(9):1513–1523.
94. Airas L, Nylund M, Rissanen E. Evaluation of Microglial Activation in Multiple Sclerosis Patients Using Positron Emission Tomography. Front Neurol 2018;9.
95. Kang Y, Gauthier SA. PET is necessary to make the next step forward in understanding MS pathophysiology – Commentary. Mult Scler J. 2019;25:1090–1.
96. Oh U, Fujita M, Ikonomidou VN, et al. Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol Off J Soc Neuro Immun Pharmacol. 2011;6:354–61.
97. Bunai T, Terada T, Kono S, et al. Neuroinflammation following disease modifying therapy in multiple sclerosis: A pilot positron emission tomography study. J Neurol Sci. 2018;385:30–3.
98. Sucksdorf M, Tuisku J, Matilainen M, et al. Natalizumab treatment reduces microglial activation in the white matter of the MS brain. Neurology. 2019;6:574.
99. Sucksdorf M, Rissanen E, Tuisku J, et al. Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis. J Nucl Med Off Publ Soc Nucl Med. 2017;58:1646–51.
100. Kaunzer UW, Kang Y, Monohan E, et al. Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation. Mult Scler Relat Disord. 2017;15:27–33.
101. Ratchford JN, Endres CJ, hammoud DA, et al. Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol. 2012;259:1199–205.
102. Kang Y, Schlyer D, Kaunzer UW, et al. Comparison of two different methods of image analysis for the assessment of microglial activation in patients with multiple sclerosis using (R)-[N-methyl-carbon-11]PK11195. PLoS ONE. 2018;13:e0201289.
103. Colasanti A, Guo Q, Muhlert N, et al. In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET. J Nucl Med Off Publ Soc Nucl Med. 2014;55:1112–8.
104. Park E, Gallego J-D, Delgaldejo A, et al. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging. 2015;42:1081–92.
105. Sridharan S, Raffel J, Nandsorak A, et al. Confirmation of Specific Binding of the 18-KDa Translocator Protein (TSPO) Radioligand [18F]FE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. Mol Imaging Biol. 2019;21:935–44.
106. Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzo diazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. 2000;123:2321–37.
107. Politis M, Giannetti P, Su P, et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology. 2012;79:523–30.
108. Herranz E, Gianni C, Louapre C, et al. Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol. 2016;80:776–90.
109. Rissanen E, Tuisku J, Rokka J, et al. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand (11)C-PK11195. J Nucl Med Off Publ Soc Nucl Med. 2014;55:939–44.
110. Giannetti P, Politis M, Su P, et al. Microglial activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. Neurobiol Dis. 2014;65:203–10.
111. Sucksdorf M, Matilainen M, Tuisku J, et al. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. Brain J Neurol 2020;143(11):3318–3330.
112. Datta G, Colasanti A, Rabiner EA, et al. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. Brain J Neurol. 2017;140:2927–38.

113. Bodini B, Poirion E, Tonietto M, et al. Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis. J Nucl Med Off Publ Soc Nucl Med. 2020;61:1043–9.

114. Kumar A, Chugani HT, Chakraborty P, et al. Evaluation of neuroinflammation in X-linked adrenoleukodystrophy. Pediatr Neurol. 2011;44:143–6.

115. De Picker L, Ottow J, Verhaeghe J, et al. State-associated changes in longitudinal [18F]-PBR11. TSPO PET imaging of psychosis patients: Evidence for the accelerated ageing hypothesis? Brain Behav Immun. 2019;77:46–54.

116. De Picker LJ, Morrens M, Chance SA, et al. Microglia and Brain Plasticity in Acute Psychosis and Schizophrenia Illness Course: A Meta-Review. Front Psychiatry 2017;8.

117. Marques TR, Ashok AH, Pillinger T, et al. Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies. Psychol Med. 2019;49:2186–96.

118. Plavén-Sigry P, Matheson GJ, Collste K, et al. Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. Biol Psychiatry. 2018;84:433–42.

119. De Picker L, Morrens M. Perspective: Solving the Heterogeneity Conundrum of TSPO PET Imaging in Psychosis. Front Psychiatry 2020;11.

120. Sneeboer MAM, van der Doel T, Lijtens M, et al. Microglial activation in schizophrenia: Is translocator 18 kDa protein (TSPO) the right marker? Schizophr Res. 2020;215:167–72.

121. Su L, Faluyi YO, Hong YT, et al. Neuroinflammation and morphological changes in late-life depression: the NIMROD study. Br J Psychiatry J Ment Sci. 2016;209:525–6.

122. Holmes SE, Hinz R, Conen S, et al. Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. Biol Psychiatry. 2018;83:61–9.

123. Turkheimer FE, Althubaiti N, Schubert J, et al. Increased serum peripheral C-reactive protein is associated with reduced brain barriers permeability of TSPO radioligands in healthy volunteers and depressed patients: implications for inflammation and depression. Brain Behav Immun. 2021;91:487–97.

124. Setiawan E, Wilson AA, Mizzrati R, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72:268–75.

125. Li H, Sagar AP, Kéri S. Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder. J Affect Disord. 2018;241:305–10.

126. Li H, Sagar AP, Kéri S. Translocator protein (18kDa TSPO) binding, a marker of microglia, is reduced in major depression during cognitive-behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;83:1–7.

127. Setiawan E, Attwells S, Wilson AA, et al. Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. Lancet Psychiatry. 2018;5:339–47.

128. Attwells S, Setiawan E, Rusjan PM, et al. Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder. Biol Psychiatry 2020;88(8):649–656.

129. Attwells S, Setiawan E, Wilson AA, et al. Replicating predictive serum correlates of greater translocator protein distribution volume in brain. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2020;45:925–31.

130. Hannestad J, DellaGioia N, Gallezot J-D, et al. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [11C]PBR28 PET study. Brain Behav Immun. 2013;33:131–8.

131. Richards EM, Zanotti-Fregonara P, Fujita M, et al. PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. EJNMMI Res. 2018;8:57.

132. Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019;81:24–40.

133. Schubert JJ, Veronese M, Fryer TD, et al. A Modest Increase in 11C-PK11195-Positron Emission Tomography TSPO Binding in Depression Is Not Associated With Serum C-Reactive Protein or Body Mass Index. Biol Psychiatry Cogn Neurosci Neuroimaging 2021;6(7):716–724.

134. Dahoun T, Calcia MA, Veronese M, et al. The association of psychosocial risk factors for mental health with a brain marker altered by inflammation: A translocator protein (TSPO) PET imaging study. Brain Behav Immun. 2019;80:742–50.

135. Sekine Y, Ouchi Y, Sugihara G, et al. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci Off J Soc Neurosci. 2008;28:5756–61.

136. Narendran R, Lopresti BJ, Mason NS, et al. Cocaine abuse in humans is not associated with increased microglial activation: an 18-kDa translocator protein positron emission tomography imaging study with [11C]PBR28. J Neurosci Off J Soc Neurosci. 2014;34:9945–50.

137. Hillmer AT, Sandiego CM, Hannestad J, et al. In vivo imaging of translocator protein, a marker of activated microglia, in alcohol dependence. Mol Psychiatry. 2017;22:1759–66.

138. Kalk NJ, Guo Q, Owen D, et al. Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [11C]PBR28 PET study. Transl Psychiatry. 2017;7:e996.

139. Kim SW, Wiers CE, Tyler R, et al. Influence of alcoholism and cholesterol on TSPO binding in brain: PET [11C]PBR28 studies in humans and rodents. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2018;43:1832–9.

140. Hillmer AT, Matskey D, Huang Y, et al. Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study. J Nucl Med Off Publ Soc Nucl Med. 2020;61:1200–4.

141. Brody AL, Hubert R, Enoki R, et al. Effect of Cigarette Smoking on a Marker for Neuroinflammation: A [11C]DAA1106 Positron Emission Tomography Study. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2017;42:1630–9.

142. Brody AL, Gehlbach D, Garcia LY, et al. Effect of overnight smoking abstinence on a marker for microglial activation: a [11C]DAA1106 positron emission tomography study. Psychopharmacology. 2018;235:3525–34.

143. London ED, Okita K, Kinney KR, et al. No significant elevation of translocator protein binding in the brains of recently abstinent methamphetamine users. Drug Alcohol Depend. 2020;213:108104.

144. Da Silva T, Hafizi S, Watts JJ, et al. In Vivo Imaging of Translocator Protein in Long-term Cannabis Users. JAMA Psychiatry 2019;76(12):1305–1313.

145. Rathinharan G, Truong J, Tong J, et al. Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18 kDa translocator protein radioligand [F-18]FEPPA. Addict Biol 2020;e12876.

146. Haarman BCMB, Riemersma-Van der Lek RF, de Groot JC, et al. Neuroinflammation in bipolar disorder - A [(11)C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun. 2014;40:219–25.
147. Haarman BCM “Benno,” Burger H, Doorduin J, et al. Volume, metabolites and neuroinflammation of the hippocampus in bipolar disorder - A combined magnetic resonance imaging and positron emission tomography study. Brain Behav Immun. 2016;56:21–33.

148. Attwells S, Setiawan E, Wilson AA, et al. Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. JAMA Psychiat. 2017;74:833–40.

149. Yokokura M, Takebashi K, Takao A, et al. In vivo imaging of dopamine D1 receptor and activated microglia in attention-deficit/hyperactivity disorder: a positron emission tomography study. Mol Psychiatry 2020. https://doi.org/10.1038/s41380-020-0784-7.

150. Bhatt S, Hillmer AT, Girgenti MJ, et al. PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transcriptomic studies. Nat Commun. 2020;11:2360.

151. Alshelleh Z, Abrecht DS, Bergan C, et al. In-vivo imaging of neuroinflammation in veterans with Gulf War illness. Brain Behav Immun. 2020;87:498–507.

152. Kumar A, Williams MT, Chugani HT. Evaluation of basal ganglia and thalamic inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection and tourette syndrome: a positron emission tomographic (PET) study using 11C-[R]-PK11195. J Child Neurol. 2015;30:749–56.

153. Suzuki K, Sugihara G, Ouchi Y, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiat. 2013;70:49–58.

154. Zürcher NR, Loggia ML, Mullette JE, et al. [11C]PBR28 MR-PET imaging reveals lower regional brain expression of translocator protein (TSPO) in young adult males with autism spectrum disorder. Mol Psychiatry 2021;26(5):1659–1669.

155. Hammoud DA, Endres CJ, Chander AR, et al. Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol. 2005;11:346–55.

156. Garvey LJ, Pavesi N, Politis M, et al. Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. AIDS Lond Engl. 2014;28:67–72.

157. Wiley CA, Lopresti BJ, Becker JT, et al. Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment. J Neurovirol. 2006;12:262–71.

158. Vera JH, Guo Q, Cole JH, et al. Neuroinflammation in treated HIV-positive individuals: A TSPO PET study. Neurology. 2016;86:1425–32.

159. Boerwinkle AH, Strain JF, Burdo T, et al. Comparison of [11C]-PBR28 binding between persons living with HIV and HIV uninfected individuals. J Acquir Immune Defic Syndr. 2020;85(2):244–251.

160. Boerwinkle A, Ances BM. Molecular Imaging of Neuroinflammation in HIV. J Neuroimmune Pharmacol. 2019;14:9–15.

161. Coughlin JM, Yang T, Rebman AW, et al. Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET. J Neuroinflammation. 2018;15:346.

162. Cagnin A, Myers R, Gunn RN, et al. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain. 2001;124:2014–27.

163. Grover VPB, Pavesi N, Koh S-B, et al. Cerebral microglial activation in patients with hepatitis c: in vivo evidence of neuroinflammation. J Viral Hepat. 2012;19:e89–96.

164. Pfugrad H, Meyer G-J, Dirks M, et al. Cerebral microglia activation in hepatitis C virus infection correlates to cognitive dysfunction. J Viral Hepat. 2016;23:348–57.

165. Dimber R, Guo Q, Bishop C, et al. Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1-Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using 11C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging. J Nucl Med Off Publ Soc Nucl Med. 2016;57:1905–12.

166. Cagnin A, Taylor-Robinson SD, Forton DM, et al. In vivo imaging of cerebral "peripheral benzodiazepine binding sites" in patients with hepatic encephalopathy. Gut. 2006;55:547–53.

167. Iversen P, Hansen DA, Bender D, et al. Peripheral benzodiazepine receptors in the brain of cirrhosis patients with manifest hepatic encephalopathy. Eur J Nucl Med Mol Imaging. 2006;33:810–6.

168. Abid KA, Sobowale OA, Parkes LM, et al. Assessing Inflammation in Acute Intracerebral Hemorrhage with [11C]PET and Dynamic Contrast-Enhanced MRI. J Neuroimaging Off J Am Soc Neuroimaging. 2018;28:158–61.

169. Gulyás B, Tóth M, Schain M, et al. Evolution of microglial activation in ischaemic core and peri-infarct regions after stroke: a PET study with the TSPO molecular imaging biomarker ([111]C)vinpocetine. J Neurol Sci. 2012;320:110–7.

170. Ribeiro M-J, Vercouillie J, Debiass S, et al. Could (18) F-DPA-714 PET imaging be interesting to use in the early post-stroke period? JENMNI Res. 2014;4:28.

171. Gerhard A, Schwarz J, Myers R, et al. Evolution of microglial activation in patients with ischemic stroke: a [11C]-(R)-PK11195 PET study. Neuroimage. 2005;24:591–5.

172. Thiel A, Radlinska BA, Paquette C, et al. The temporal dynamics of poststroke neuroinflammation: a longitudinal diffusion tensor imaging-guided PET study with 11C-PK11195 in acute subcortical stroke. J Nucl Med. 2010;51:1404–12.

173. Wright P, Veronese M, Mazibuko N, et al. Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An in vivo PET Study With Neuropathological Comparison. Front Neurol. 2020;11:541377.

174. Gaemperli O, Shalhoub J, Owen DRJ, et al. Imaging intraplaque inflammation in carotid atherosclerosis with [11C]PK11195 positron emission tomography/computed tomography. Eur Heart J 2011.

175. Verweij SL, Strekova LCA, Delewii R, et al. Prolonged hematopoietic and myeloid cellular response in patients after an acute coronary syndrome measured with 18F-DPA-714 PET/CT. Eur J Nucl Med Mol Imaging. 2018;45:1956–63.

176. Pugliese F, Gaemperli O, Kinderlerer AR, et al. Imaging of Vascular Inflammation With [11C]-PK11195 and Positron Emission Tomography/Computed Tomography Angiography. J Am Coll Cardiol. 2010;56:653–61.

177. Lamare F, Hinz R, Gaemperli O, et al. Detection and Quantification of Large-Vessel Inflammation with 11C-(R)-PK11195 PET/CT. J Nucl Med. 2011;52:33–9.

178. Backhaus P, Roll W, Beuker C, et al. Initial experience with [18F] DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system. Eur J Nucl Med Mol Imaging. 2020;47:2131–41.

179. Folkersma H, Boellaard R, Yaquub M, et al. Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injury. J Nucl Med Off Publ Soc Nucl Med. 2011;52:1235–9.

180. Ramlackhansingh AF, Brooks DJ, Greenwood RJ, et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011;70:374–83.
181. Scott G, Hellyer PJ, Ramlachhansingh AF, et al. Thalamic inflammation after brain trauma is associated with thalamo-cortical white matter damage. J Neuroinflammation. 2015;12:224.

182. Coughlin JM, Wang Y, Munro CA, et al. Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. Neurobiol Dis. 2015;74:58–65.

183. Coughlin JM, Wang Y, Minn I, et al. Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. JAMA Neurol. 2017;74:67–74.

184. Scott G, Zetterberg H, Jolly A, et al. Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. Brain J Neurol. 2018;141:459–71.

185. Peters ME, Rahman S, Coughlin JM, et al. Characterizing the Link Between Glial Activation and Changed Functional Connectivity in National Football League Players Using Multimodal Neuroimaging. J Neuropsychiatry Clin Neurosci. 2020;32:191–5.

186. Junck L, Olson JM, Ciliax BJ, et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol. 1989;26:752–8.

187. Kreisl WC, Lawrence R, Page E, et al. 11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease. Neurology. 2017;88:1001–4.

188. Su Z, Roncarioli F, Durrenberger PF, et al. The 18-kDa mitochondrial translocator protein in human gliomas: an 11C-(R)PK11195 PET imaging and neuropathology study. J Nucl Med Off Publ Soc Nucl Med. 2015;56:512–7.

189. Unterrainer M, Fleischmann DF, Diekmann C, et al. Comparison of 18F-GE-180 and dynamic 18F-PET translocator PET in high grade glioma: a double-tracer pilot study. Eur J Nucl Med Mol Imaging. 2019;46:580–90.

190. Zimmhardt B, Mühler M, Roll W, et al. TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. Neuro-Oncol. 2020;22:1030–43.

191. Tran TT, Gallezot J-D, Jilaveanu LB, et al. [11C]Methionine and [11C-PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. Mol Imaging. 2020;19:1536012120968669.

192. Hirvonen J, Kreisl WC, Fujita M, et al. Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy. J Nucl Med Off Publ Soc Nucl Med. 2012;53:234–40.

193. Fujita M, Mahantry S, Zoghbi SS, et al. PET reveals inflammation around calcified Taenia solium granulomas with perilesional edema. PLoS ONE. 2013;8:e74052.

194. Dickstein LP, Liow J-S, Austermuehle A, et al. Neuroinflammation in neocortical epilepsy measured by PET translocator protein. Epilepsia. 2019;60:1248–54.

195. Kumar A, Chugani HT, Luat A, et al. Epilepsy surgery in a case of encephalitis: use of 11C-PK11195 positron emission tomography. Pediatr Neurol. 2008;38:439–42.

196. van der Laken CJ, Elzinga EH, Kropholler MA, et al. Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum. 2008;58:3350–5.

197. Gent YJY, Voskuyil AE, Kloet RW, et al. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. Arthritis Rheum. 2012;64:62–6.

198. Gent YJY, Ahmadi N, Voskuyil AE, et al. Detection of subclinical synovitis with macrophage targeting and positron emission tomography in patients with rheumatoid arthritis without clinical arthritis. J Rheumatol. 2014;41:2145–52.

199. Narayan N, Owen DR, Mandhair H, et al. Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus. J Nucl Med Off Publ Soc Nucl Med. 2018;59:1125–32.

200. de Groot M, Patel N, Manavaki R, et al. Quantifying disease activity in rheumatoid arthritis with the TSPO PET ligand 18F-GE-180 and comparison with 18F-FDG and DCE-MRI. EJNNMI Res. 2019;9:113.

201. Helo Y, Scarle GE, Borghese F, et al. Specificity of translocator protein-targeted positron emission tomography in inflammatory joint disease. EJNNMI Res. 2020;10:147.

202. Forsberg A, Lamp A, Estelius J, et al. Disease activity in rheumatoid arthritis is inversely related to cerebral TSPO binding assessed by [11C]PBR28 positron emission tomography. J Neuroimmunol. 2019;334:577000.

203. Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-(R)-PK11195 PET Study. J Nucl Med Off Publ Soc Nucl Med. 2014;55:945–50.

204. Albrecht DS, Forsberg A, Sandström A, et al. Brain glial activation in fibromyalgia - A multi-site positron emission tomography investigation. Brain Behav Immun. 2019;75:72–83.

205. Loggia ML, Chonde DB, Akeju O, et al. Evidence for brain glial activation in chronic pain patients. Brain J Neurol. 2015;138:604–15.

206. Albrecht DS, Ahmed SU, Kettner NW, et al. Neuroinflammation of the spinal cord and nerve roots in chronic radicular pain patients. Pain. 2018;159:968–77.

207. Albrecht DS, Kim M, Akeju O, et al. The neuroinflammatory component of negative affect in patients with chronic pain. Mol Psychiatry 2021 Mar;26(3):864–874

208. Torrado-Carvajal A, Toschi N, Albrecht DS, et al. Thalamic neuroinflammation as a reproducible and discriminating signature for chronic low back pain. Pain 2021;162(4):1241–1249

209. Jeon SY, Seo S, Lee JS, et al. [11C)-(R)-PK11195 positron emission tomography in patients with complex regional pain syndrome: A pilot study. Medicine (Baltimore). 2017;96:e5735.

210. Jung Y-H, Kim H, Jeon SY, et al. Brain Metabolics and Peripheral Biomarkers Associated with Neuroinflammation in Complex Regional Pain Syndrome Using [11C)-(R)-PK11195 Positron Emission Tomography and Magnetic Resonance Spectroscopy: A Pilot Study. Pain Med Malden Mass. 2019;20:504–14.

211. Jones HA, Marino PS, Shakur BH, et al. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J. 2003;21:567–73.

212. Branley HM, du Bois RM, Wells AU, et al. PET scanning of macrophages in patients with scleroderma fibrosing alveolitis. Nucl Med Biol. 2008;35:901–9.

213. Wang Y, Coughlin JM, Ma S, et al. Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [11C]DPA-713 positron emission tomography. Lupus. 2017;26:170–80.

214. Hunter HJA, Hinz R, Gerhard A, et al. Brain inflammation and psoriasis: a [11 C]-(R)-PK11195 positron emission tomography study. Br J Dermatol. 2016;175:1082–4.

215. Tamm S, Cervenka S, Forsberg A, et al. Evidence of fatigue, disordered sleep and peripheral inflammation, but not increased brain TSPO expression, in seasonal allergy: A [11C]PBR28 PET study. Brain Behav Immun. 2018;68:146–57.

216. Banati RB, Cagnin A, Brooks DJ, et al. Long-term trans-synaptic glial responses in the human thalamus after peripheral nerve injury. Neuro Report. 2001;12:3439–42.

217. Chugani HT, Kumar A. Neuroinflammation in Children With Infantile Spasms: A Prospective Study Before and After Treatment With Acthar Gel (Repository Corticotropin Injection). J Child Neurol 2020;83073820932710

218. Best L, Ghadery C, Pavese N, et al. New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation
in Neurodegenerative Disease. Curr Neurol Neurosci Rep. 2019;19:24.

219. Ghadery C, Best LA, Paveze N, et al. PET Evaluation of Microglial Activation in Non-neurodegenerative Brain Diseases. Curr Neurol Neurosci Rep. 2019;19:38.

220. Dimitrova-Shumkovska J, Krstanoski L, Veenman L, Diagnostic and Therapeutic Potential of TSPO Studies Regarding Neurodegenerative Diseases, Psychiatric Disorders, Alcohol Use Disorders, Traumatic Brain Injury, and Stroke: An Update. Cells. 2020;9:870.

221. Downer OM, Marcus REG, Zürcher NR, et al. Tracing the History of the Human Translocator Protein to Recent Neurodegenerative and Psychiatric Imaging. ACS Chem Neurosci. 2020;11:2192–200.

222. Chaney A, Williams SR, Boutin H. In vivo molecular imaging of neuroinflammation in Alzheimer’s disease. J Neurochem. 2019;149:438–51.

223. Ishibashi K, Miura Y, Imamura A, et al. Microglial Activation on 11C-CB184 PET in a Patient With Cerebellar Ataxia Associated With HIV Infection. Clin Nucl Med. 2018;43:e82–4.

224. Takano A, Piehl F, Hillert J, et al. In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F] FEDAA1106. EJNMMI Res. 2013;3:30.

225. Varrone A, Mattsson P, Forsberg A, et al. In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer’s disease patients. Eur J Nucl Med Mol Imaging. 2013;40:921–31.

226. Varrone A, Oikonen V, Forsberg A, et al. Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer’s disease patients and control subjects. Eur J Nucl Med Mol Imaging. 2015;42:438–46.

227. Singhal T, O’Connor K, Dubey S, et al. Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. Neurol Neuroimmunol Neuroinflammation. 2019;6:e587.

228. Singhal T, Cicero S, Pan H, et al. Regional microglial activation in the substantia nigra is linked with fatigue in MS. Neurol Neuroimmunol Neuroinflammation 2020;7(5):e854

229. Gulyás B, Vas A, Tóth M, et al. Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with [11C]vinpocetine. Neuroimage. 2011;56:1111–21.

230. Colasanti A, Guo Q, Giannetti P, et al. Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis. Biol Psychiatry. 2016;80:62–72.

231. Datta G, Colasanti A, Kalk N, et al. 11C-PBR28 and 18F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. J Nucl Med Off Publ Soc Nucl Med. 2017;58:1477–82.

232. Ottow J, De Packer L, Verhaeghe J, et al. 18F-PBR111 PET Imaging in Healthy Controls and Schizophrenia: Test-Retest Reproducibility and Quantification of Neuroinflammation. J Nucl Med Off Publ Soc Nucl Med. 2018;59:1267–74.

233. Zanotti-Fregonara P, Pascual B, Rizzoli G, et al. Head-to-Head Comparison of 11C-PBR28 and 18F-GE180 for Quantification of the Translocator Protein in the Human Brain. J Nucl Med Off Publ Soc Nucl Med. 2018;59:1260–6.

234. Zanotti-Fregonara P, Veronese M, Pascual B, et al. The validity of 18F-GE180 as a TSPO imaging agent. Eur J Nucl Med Mol Imaging. 2019;46:1205–7.

235. Zanotti-Fregonara P, Pascual B, Rostomily RC, et al. Anatomy of 18F-GE180, a failed radioligand for the TSPO protein. Eur J Nucl Med Mol Imaging. 2020;47:2233–6.